The PPARγ antagonist GW9662 inhibited the progression and metastasis of BC by selectively reducing PD-L1 expression in mouse adipose tissue and enhanced the antitumor effect of CD8+ T cells in homozygous BC models [141]. Here, CD8A is linked to breast cancer.